The concept of manipulating the gut microbiota through the administration of probiotics during early life in order to reduce the risk of and prevent or treat diseases, including those that manifest in later life, is appealing. However, a cautious approach is needed, and the long-term consequences of such administration should be carefully evaluated. Concerns related to the early administration of probiotics include timing, i.e. the administration often begins in early infancy, sometimes at birth, when gut microbiota is not fully established, and duration, i.e. the daily administration of such products is prolonged (several weeks or months). In the case of non-breastfed infants, delivery may be in the form of a specific matrix (infant formula) that could be the only source of feeding of an infant over a prolonged period. Finally, the fact that beneficial as well as some detrimental effects are seen years after administration of probiotics during the first months of life raises concern that other long-term effects such as immunosuppression in later life may also occur. Currently, while some promising data exist, there are still more questions than answers. However, rapid progress in this area of research is expected and no doubt will bring about a number of exciting findings.
Introduction
Interest of parents and health care providers with regard to infant nutrition is shifting towards health benefits beyond the provision of nutritional requirements. Emerging evidence suggests that the microbiota disturbances during early life may have consequences extending into adulthood. The pathogenesis of such diseases as asthma, allergy, atopy, type 1 diabetes, and inflammatory bowel disease has been linked to abnormal intestinal colonization. This has led to an interest in the development of strategies aimed at manipulating the composition and metabolic activity of the gut microbiota, including the administration of probiotics or prebiotics or a combination of both (synbiotics) during early life. These products are currently gaining worldwide popularity and are increasingly being used in the pediatric population, including very young infants, despite some reservations regarding their efficacy and safety in this vulnerable population.
There are a number of issues and concerns related to the administration of probiotics, defined as microbial food supplements which, when administered in adequate amounts, have a beneficial effect on the host [1] , early in life. First, the timing, i.e. the administration often begins in early infancy, sometimes at birth. Thus, the onset of administration is at a time when the gut microbiota is not fully established, and factors that influence microbiota may potentially permanently affect the development of the ecosystem. Second, the duration, i.e. the daily administration of such products is over a long time (several weeks or months). Third, in the case of non-breastfed infants, delivery may be in the form of a specific matrix (infant formula) that could be the only source of feeding of an infant over a prolonged period of time. This is in contrast to older children and adults in whom consumption of a probiotic product constitutes only a portion of their diets. Finally, evidence from at least one study with a long follow-up period documented that beneficial as well as unfavorable effects are seen years after the administration of probiotics during pregnancy and during the first months of life [2, 3] . Such an observation raises concern that other long-term effects, such as immunosuppression, may also occur in later life.
In this paper, the literature concerning the short-and long-term health effects of administering probiotics during early postnatal life, i.e. during the first weeks/months of life, both to preterm and term infants is summarized. For this purpose, the MEDLINE and the Cochrane Library databases were searched in September 2010. Priority was given to randomized controlled trials (RCTs) or their systematic reviews or meta-analyses. Further references were identified from the original articles and recent review articles. Evidence-based clinical practice guidelines developed by respected scientific societies or expert groups were also considered. The primary interest was in clinically relevant, short-term and long-term efficacy outcomes, such as those related to a reduced risk of disease, as well as in outcomes related to safety. Studies reporting the effects of probiotics administered beyond early infancy, whether for prophylactic or therapeutic reasons, have been discussed in detail elsewhere and are not reviewed here.
Probiotics for Preterm Infants
The rationale for probiotic supplementation of preterm infants is based on data demonstrating differences in the establishment of the intestinal microbiota in preterm infants. Compared with healthy, full-term infants, the intestinal microbiota in preterm infants features a low number of species, and there is significantly delayed colonization with anaerobes, especially bifidobacteria [4] [5] [6] . Additionally, preterm infants are often cared for in intensive care units and receive broad-spectrum antibiotics, which further contributes to differences in colonization patterns. The possible consequences of abnormal patterns of colonization in preterm infants to health are not known. However, it has been speculated that they may contribute to increased susceptibility to infections and the pathogenesis of necrotizing enterocolitis (NEC). The latter is one of the most serious, life-threatening, gastrointestinal diseases, and it is characterized by various degrees of mucosal or transmural necrosis of the intestine. The incidence of NEC in infants is 5-10% [7] . The highest incidence is reported in infants with birthweights below 1,000 g, and the incidence decreases with increasing birthweights [8] . The exact cause of NEC remains unclear. However, in addition to prematurity, factors such as formula feeding, intestinal hypoxia-ischemia, and colonization with pathogenic microbiota are considered to play a role in the pathogenesis of NEC [9] . While clearly the most effective strategy for preventing NEC is feeding with human milk, it has also been suggested that the enteral administration of probiotics to preterm newborns could prevent infections, prevent NEC, and reduce the use of antibiotics [10] .
A number of systematic reviews, with or without a meta-analysis, have reviewed data on the effects of the enteral administration of probiotics on the risks of NEC and mortality in preterm infants [11] [12] [13] [14] . Among them, the most recent is the updated meta-analysis by Deshpande et al. [14] (search date: March 2009), which identified 11 RCTs, including 4 recent trials, and involved 2,176 preterm infants. Compared with the control group, preterm neonates in the probiotic group had a reduced risk of NEC (relative risk, RR, 0.35, 95% confidence interval, CI, 0.23-0.55) and all-cause mortality (RR 0.42, 95% CI 0.29-0.62), but there was no difference between groups in the risk of sepsis (RR 0.98, 95% CI 0.81-1.18). Heterogeneity between trials was low (I 2 = 0%), suggesting that the benefit appears to be a true class effect despite known differences between individual probiotic microorganisms.
From a methodological point of view, this is a high-quality meta-analysis the results of which should be reliable and valid. The major concern with regard to this meta-analysis, as with many other meta-analyses in the area of probiotics, is whether it is appropriate to pool data on different microorganisms. Arguments for and against pooling data on different probiotics are presented in table 1 [15] .
The findings of this meta-analysis have potentially important clinical and public health implications, and thus should be taken into careful consideration. Should this meta-analysis alter our practice? Recently, the Committee on Nutrition (CoN) of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) concluded that the presently available data do not permit recommending the routine use of prebiotics or probiotics as food supplements in preterm infants to prevent NEC. The Committee also recommended that each probiotic strain and potential combinations need to be characterized separately for each product [16] . This position does not mean that the use of probiotics for preventing NEC should be totally discarded. Rather, in settings in which the incidence of NEC is high, one may consider the use of probiotics -single or in combination. However, care should be given to choose those that are the best studied, with the highest effect size, and the best safety profile [17] . In this respect, figure 1 depicts a meta-analysis of the effects of probiotics for preventing NEC, with subgroup analyses based on the type of probiotic administered. In addition to data presented in the meta-analysis by Deshpande et al. [14] , it also includes the results of one of the most recently published trials [18] . It clearly shows that while evidence regarding the potential beneficial effects of probiotic supplementation in preterm infants is encouraging, not all probiotic microorganisms are equal in preventing NEC. Of note, with the exception of Bifidobacterium lactis Bb12 and Lactobacillus rhamnosus GG, there are no data from more than single studies on given probiotic microorganism(s).
With regard to the long-term effects of probiotic administration to preterm infants, only one trial has addressed this issue thus far. Participants in an RCT designed to evaluate the efficacy of probiotics in preventing NEC were subsequently enrolled in a follow-up study. Oral administration of Lactobacillus acidophilus and Bifidobacterium infantis at 1 week after birth until discharge had no effect on growth, neurodevelopmental outcomes, and sensory outcomes at 3 years corrected age [19] . Overall, certain probiotics prevent NEC. Whether probiotic supplementation should become the standard of care is still under discussion. Before the routine use of probiotics in preterm infants, data regarding which products should be administered, at what dose, and for how long are needed. While awaiting new studies and consensus among specialists, it seems reasonable to discuss with parents current evidence regarding probiotics and let them decide whether the intervention might be beneficial.
Probiotics in Infant Formulae
In 2010, the ESPGHAN CoN systematically reviewed published evidence related to the safety and health effects of the administration of formulae supplemented with probiotics compared with unsupplemented formulae [20] . RCTs and quasi-RCTs (defined as studies in which the participants are allocated to different interventions using methods that are not random; for example, allocation may be based on the person's date of birth) or their systematic reviews/ meta-analyses were considered for inclusion. Overall, 20 publications met the inclusion criteria. The methodological quality of the included RCTs varied. The most common problems were a lack of description of randomization procedures and/or allocation concealment. Many trials were underpowered for the assessment of specific outcomes. Only studies carried out in healthy term infants were included. The studies varied in the types of probiotics used. The most commonly studied probiotic was Bifidobacterium animalis ssp. lactis CNCMI-3446 (previously known as Bifidobacterium bifidum or B. lactis Bb-12); this probiotic was administered either alone, in combination with Streptococcus thermophilus, or in combination with S. thermophilus and Lactobacillus helveticus. Other probiotics studied were Lactobacillus acidophilus johnsonii La1, Bifidobacterium longum BL999 (BL999) and Lactobacillus rhamnosus LPR (LPR), LGG, Lactobacillus reuteri ATCC 55730, and Lactobacillus salivarius CECT5713. The doses of probiotics varied considerably. Also, the supplementation periods varied from 15 days to 8 months.
The Committee evaluated the following 2 ways of administering probioticsupplemented formula: (1) administration that was started in infants £4 months of age (or ≤6 months of age provided they had not started complementary feeding) and continued for at least 2 weeks, and (2) administration of probiotic-supplemented infant or follow-on formula at any other age beyond early infancy and regardless of the duration of the intervention. Overall, the Committee concluded that for healthy infants, available scientific data suggest that the administration of probiotic-supplemented formula to infants does not raise safety concerns with regard to growth and short-term adverse effects. The administration of probiotic-supplemented infant formula during early life (≤4 months of age) does not result in any consistent clinical effects. The administration of a few probiotics supplemented to infant or However, the available studies varied in methodological quality, the specific probiotics studied, the durations of the interventions, and the doses used. The Committee considered there is still too much uncertainty to draw reliable conclusions from the available data. The safety and clinical effects of one probiotic microorganism should not be extrapolated to other probiotic microorganism(s). In general, there is a lack of data on the longterm effects of the administration of formula supplemented with probiotics. The Committee stressed that such data would be of particular importance if the effects persist after the administration of the probiotic(s) has ceased.
Other Studies
A number of studies have evaluated the effects of probiotics introduced early in life but not in infant formula. Instead, they were administered in capsules, the contents of which were supplemented to breast milk and/or infant formula or given to an infant only. As these studies were not included in the systematic review carried out by the ESPGHAN CoN, they are briefly discussed below.
Primary Allergy Prevention
The rationale for using probiotics in the prevention of atopic disorders is based on several concepts. First, it has been suggested that improved hygiene and the reduced exposure of the immune system to the microbial stimulus early in childhood contribute to the rising number of allergic disorders worldwide [21] . Second, there are differences in the neonatal gut microflora that may either precede or coincide with the early development of atopy. Atopic subjects have more clostridia and tend to have fewer bifidobacteria species in their fecal microbiota than non-atopic subjects [22] . Finally, there is evidence suggesting a crucial role for a balanced commensal gut microflora in the maturation of the early immune system.
Clinical research on the effects of probiotic administration early in life on allergy prevention started only about a decade ago. So far, the evidence is conflicting. A recent Cochrane Review concluded that there is insufficient evidence to recommend the addition of probiotics to infant feeds for the prevention of allergic diseases, including food hypersensitivity [23] . However, a meta-analysis by Lee at al. [24] demonstrated that the prenatal and/or postnatal administra-tion of probiotics to pregnant women and their infants resulted in a significant reduction in the incidence of atopic dermatitis in the infants. The authors of a third review also concluded that probiotics, especially Lactobacillus GG, seem to be effective in the prevention of atopic dermatitis [25] .
As pointed our earlier, the merit of pooling data obtained on different probiotic strains, with no analyses based on probiotic strain(s), is questionable (table 1) . The meta-analysis by Lee et al. [24] can be furthermore criticized for combining data from the same study population at different time intervals. Meta-analytical purists may also disagree with combining the results from 5 studies on probiotics with results from one study on synbiotics. Moreover, due to its subsequent publication, none of these meta-analyses included the recent negative data related to Lactobacillus GG [26] . This important study was carried out based on a protocol almost identical to that used in an earlier positive study by Kalliomaki et al. [2, 3] with a long follow-up. The authors reported that supplementation with Lactobacillus GG during pregnancy and early infancy did not reduce either the incidence or severity of atopic dermatitis in affected children, but it increased the rate of recurrent episodes of wheezing bronchitis [26] . One additional RCT deserves discussion here. This is a double-blind RCT conducted in Finland in which 1,223 pregnant women carrying infants at high risk for the development of atopic disease were randomly assigned to receive either a combination of L. rhamnosus GG, L. rhamnosus LC705, Bifidobacterium breve Bb99, and Propionibacterium freudenreichii ssp. shermanii JS or placebo for 2-4 weeks before delivery. The infants received the same probiotic preparation plus galacto-oligosaccharides or placebo for 6 months after delivery. Clearly, simultaneous administration of probiotics and a prebiotic is not equal to the administration of probiotics only. However, the results of this study merit attention in the context of this chapter (i.e. early administration of the study products, large sample size, long follow-up). A significantly higher proportion of infants who received the probiotic/prebiotic preparation compared with placebo had a reduction in their risk of developing eczema (RR 0.81, 95% CI 0.66-0.99) and in their risk of developing atopic eczema (RR 0.70, 95% CI 0.51-0.96). However, there was no significant difference between groups in the cumulative incidence of all allergic diseases [27] . In a follow-up study that assessed outcomes at 5 years [28] , no significant differences were found between the experimental and placebo groups in the frequencies of allergic disease, IgE-associated allergic disease, sensitization, eczema, atopic eczema, allergic rhinitis, and asthma. However, less IgEassociated allergic disease occurred in cesarean section-delivered children who received probiotics plus galacto-oligosaccharides compared with placebo (24.3 vs. 40.5%; p = 0.035). Thus, the preparation containing probiotics and prebiotics, at least as used in this study, did not result in an allergy-preventive effect that extended until the age of 5 years except in a subgroup of children delivered by cesarean section.
Overall, research in the area of prevention of allergic disorders through modification of intestinal microbiota is relatively new. Currently, there is insufficient evidence to recommend the addition of probiotics to infant feeds for the prevention of allergic disease. Long-term RCTs are necessary to establish whether manipulation of the gut microbiota can safely decrease the risk of allergic disease. If yes, we need to determine which microorganisms are suitable and in which type of population.
Prevention of Acute Infections
The immunomodulatory effects of probiotics have been studied extensively in both in vitro and animal models. The question that remains, however, is what is the clinical relevance of such immune modulation?
In a double-blind RCT, Finish investigators assigned 81 infants before the age of 2 months to receive probiotics (Lactobacillus GG and B. lactis Bb12) or placebo daily until the age of 12 months. The probiotics were administered in capsules, the contents of which were supplemented to infant formula. With regard to the primary outcomes, a group of 72 infants was available for the analysis. During the first 7 months of life, there was no significant difference between the probiotics and placebo groups in the incidence of gastrointestinal infections (RR 0.21, 95% CI 0.03-1.64) or respiratory infections (RR 0.89, 95% CI 0.67-1.18). However, there was a reduced incidence of acute otitis media in the probiotics group compared with the placebo group (RR 0.44, 95% CI 0.21-0.9). In addition, the investigators reported a significant reduction in the use of antibiotics in the group of infants whose formula was supplemented with B. lactis Bb12 and LGG compared with the control formula group (RR 0.52, 95% CI 0.29-0.92) [29] .
Additional data come from the already described Finish study [27] . In 2008, these investigators reported data from a follow-up study in which a 2-year follow-up assessment was completed by 925 of 1,018 eligible infants [30] . During the 6-month intervention, there was no significant difference between the probiotic/prebiotic and placebo groups in the occurrence (at least once) of respiratory infections (66 vs. 68%), middle ear infections (15 vs. 19%), or gastroenteritis (13 vs. 14%). Fewer infants received antibiotics in the experimental group than in the placebo group, although the difference was of a borderline significance (23 vs. 28%; OR 0.74; 95% CI 0.55-1.00; p = 0.049). After the intervention, during the follow-up period (6-24 months), the total number of respiratory infections was significantly lower in the probiotic/prebiotic group than in the placebo group (geometric mean: 3.7 vs. 4.2 infections; ratio: 0.87; 95% CI 0.79-0.97; p = 0.009). The authors concluded that the study indicates that feeding probiotics and prebiotics to allergy-prone infants increases their resistance to respiratory infections during the first 2 years of life [30] .
Overall, certain probiotics administered early in life have the potential to reduce the risk of various symptoms of respiratory tract infections. However, data are currently far too limited to distill any clinical recommendations.
Safety
Overall, probiotics are generally safe for use in otherwise healthy populations [31] . Still, if probiotics are to be given early in life, particularly if for a prolonged time, safety issues need special attention. As summarized earlier, the ESPGHAN CoN concluded that for healthy infants, available scientific data suggest that the administration of the probiotic-supplemented infant formulae studied so far does not raise safety concerns with regard to growth and short-term adverse effects [16] . However, the safety and clinical effects of one probiotic microorganism should not be extrapolated to other probiotic microorganism(s). In the context of the discussion here, observations made by some investigators in studies with probiotic administration during early life, such as for example higher rates of some airways symptoms in the probiotic-supplemented group [2, 32, 33] , merit further investigation.
Quality of Probiotic Products
Many clinicians have concerns regarding the reliability of some of the products currently on the market. Indeed, a number of studies have questioned the microbiological quality and labeling of many probiotic products [34] [35] [36] [37] [38] . Only some of them meet the definition of probiotics, i.e. contain viable, defined microorganisms in sufficient numbers. Products sold for medicinal purposes tend to be of better quality than probiotics used in dairy foods or probiotic supplements. Considering that the beneficial effects of probiotics seem to be strain specific and dose dependent, such results indicate the need for regulation concerning the labeling of probiotic products. Accurate labeling is essential for their proper use. Health care professionals and consumers should be aware of possible variations. Until issues are regulated, the only sound approach seems to be to choose probiotic-supplemented formula and/ or a probiotic product from a recognized manufacturer who has a regulated quality control of factors including the composition and content of the probiotic bacteria. Ideally, the safety and effectiveness of the manufacturer's product should be confirmed in well-conducted RCTs.
Conclusions
The concept of manipulating the gut microbiota through the administration of probiotics during early life in order to reduce the risk of and prevent or treat diseases, including those that manifest in later life, is appealing. However, a cautious approach is needed, and long-term consequences of such administration should be carefully evaluated. As of now, there are still more questions than answers. However, rapid progress in this area of research is expected, and no doubt will bring about a number of exciting findings.
Discussion
Dr. Villalpando: You addressed in your meta-analysis the total amount of the probiotics needed for preventive purposes. Does the dose of probiotics in supplemented milk make a difference to a preterm infant?
Dr Szajewska: The problem with the meta-analysis is that all of the probiotics were pooled together, i.e., different probiotics, doses, durations and ways of administration, given with breast milk or with formula, etc. So, I don't have a clear answer to tell you regarding what is the total dose. In most of the studies, the dose was 10 8 to 10 9 CFU. It depends very much on the study.
Dr. Villalpando: This is a very important issue in relation to obesity. The Kalliomäki group worked with the cohort that was supplemented with probiotics early in life [1] .
Dr. Szajewska: The intervention started 2 to 4 weeks before birth when probiotics were given to expecting mothers and then they were given 6 months after delivery either to breastfeeding mothers or their infants. But the children who were evaluated here were not the whole cohort, and there was no statistically significant difference in outcomes [2] . I showed it because it's something that is very often discussed. It's an interesting finding, but definitely I am not saying that we should jump to the conclusion that this particular probiotic, or any probiotic would really prevent obesity. I think it's much too early to jump to these kinds of conclusions.
Dr. Mohanty: We have an ongoing randomized controlled study in our hospital; 3 centers have been chosen under the funding of the American Health Department, and probiotics have been used in over 5,000 preterm newborn infants on days 1, 3, 5 and 7in the hospital; then, they were followed in the health centers in the rural areas. I was one of the evaluators of that study. Although we have not made a final analysis yet, the interim analysis is very encouraging. In terms of reducing infection, it has a very good salutary effect. But what is interesting is, the skin is the largest organ in the body, why are we not trying something on the surface of the skin to prevent infection maybe in the extreme preterm babies? Dr. Szajewska: That's an interesting concept. I don't really know whether it would be more effective or not; I simply don't know.
Dr. Mohanty: In Saudi Arabia in 1982, I tried administering probiotics using this method.
Dr. Szajewska: But my concern would be whether these probiotics could survive on the skin. I think there would be a number of issues regarding how to administer the probiotics, how to make sure that they would still be alive, and how to determine whether they need to be alive.
Dr. Mohanty: I used them just after delivery. But the mothers complained that I made their babies dirty and sticky, so I discontinued this.
Dr. Fasano: Soon after that, this meta-analysis was published in Pediatrics, and all the comments were associated with it; both the NIH and the FDA in the US took a very strong position. As a matter of fact, if you propose to use probiotics for improving health it's one thing, but if you propose to use probiotics with specific therapeutic indications, you leave the premises of food supplement and you come into drug development, meaning that you have to go through the same scrutiny as any drug, i.e. put together very complex and cumbersome package that's technically called IND, and then you have to go through safety and efficacy trials and so on and so forth. Interestingly enough, the NIH empowered National Center for Complementary and Alternative Medicine to be in charge of this kind of situation. The bottom line is that if you want to do any study, and it is NIH funded, there is no way that you can use any probiotic unless you address the question that you put on the table, no matter what kind of meta-analysis you go for. Not all probiotics are made equal. When penicillin was discovered, we thought we could treat any infection with it. Now we know too well that this is not the case and indiscriminate use of antibiotics can be detrimental. The same story here, probiotics probably will need to be customized to any specific intervention. So we came up with the argument that the meta-analysis for NEC, for example, is so strong to justify the use of probiotics in preterm infants. However, NIH and FDA claim that if you attempt to use probiotics for a specific indication, they need to be treated as drugs and, as such, you have to show composition, stability, if the content would change over time, the shelf life and so on. I think you were right when you said that evidence base is by no means something that needs to be disregarded; but the game with probiotics has been played in a very unusual way. We use them first and then we try to figure out how they really work, rather than the other way round.
Dr. Szajewska: I have to agree particularly with the latter comment. My position is that if we want to use probiotics as a medicine we should really do these kinds of studies. This is exactly my position.
Dr. Rings: I have a question concerning premature babies and NEC prevention. I would guess very young children with very low birthweight will profit most from probiotics, and my question is: are there sufficient data for this particular group, because they have the highest incidence of NEC? Are there enough data, to your opinion, to promote probiotics for this particular group if there are no restrictions in supplying them?
Dr. Szajewska: This issue has been raised by the authors of many meta-analyses, including the authors of the Cochrane review. There is not enough data with regard to extremely very low birth weight infants, those below 1000 g. As you said, this is a group that is particularly at risk for NEC. When I was showing one of the sub-group analyses that could be done, one option is to do it based on birth weight and gestational age. Definitely the risk is different depending on the birth weight and gestational age. I agree, not enough data.
Dr. Klish: I want to ask you a very specific question about safety which has been bothering me for the last few months since I was on a panel where this issue came up. It has to do with Lactobacillus reuteri which is one of the probiotics that you discussed. L. reuteri produces reuterin, and reuterin at least theoretically can be a mucosal toxin. The question that came up was whether it is safe to use this particular probiotic in the first few days of an infant's life when the bacterial matrix is not well developed. We know that it is safe later in life, but is it safe in your opinion in the first few days of life?
Dr. Szajewska: The problem is we simply do not have enough evidence, even though nowadays this is probably one of the best-studied probiotics. My answer would be we don't have sufficient evidence to answer yes or no.
Dr. Klish: I think that is a problem because there may be attempts to use this probiotic in that way without any knowledge of its effect.
Dr. Guandalini: A short comment on one of the points that was raised on the very low birthweight and the use of probiotics to prevent NEC. Erika Isolauri's group have recently published their retrospective experience in Finland with a number of neonatal intensive care units that have been using LGG routinely in their infants [3] .
They looked at it retrospectively, and documented that actually in some instances the use of LGG was detrimental: the prematures that received LGG had indeed a higher rate of NEC. However, if you look at the data, you would notice that all the numbers that lead to this total increase in prevalence of NEC in the probiotic-treated group refer to very low-birthweight babies. In fact, those who were 1,500 g or more had actually an equal or lower incidence of NEC. So, I believe it is fair to say that the jury is still out on this, but certainly the evidence of efficacy of probiotics in preventing NEC is quite strong. For this reason, it becomes imperative that well-controlled trials be performed in the USA, considering the reluctance that physicians in this country seem to show when it comes to accepting scientific evidence that is generated outside of the national boundaries.
Dr. Simmer: I feel I have to say something because the two meta-analyses in the Lancet and Pediatrics from people in my unit, in my team, their strong conclusion wasn't that there shouldn't be further trials, it was questioning the use of placebo in their trials. Since the paper in the Lancet, for 2 years we have done exactly what you have said, we have got every product available to us and every single one of them was insufficient, the whole thing was a disaster for 2 years. Now, we have located two, and even though the meta-analysis says not for placebo, until we use them in our 23, 24 weekers we are doing placebo but not on 4,000 infants to look at NEC, on 100 infants just to look at colonization. Future trials will be between different probiotics, between different doses, that sort of thing. So it was never that there was no need for further research, it was questioning the ethics of how long can we not give any probiotic to a premature baby with NEC.
Dr. Szajewska: Can I ask you a question? If the conclusion is that we should not do placebo-controlled trials with probiotics for preventing of NEC, which probiotic should we choose to administer to the control group? I have to say that I would have problems choosing the proper one. That's why I have some doubts about agreeing with this conclusion, I think we still need placebo-controlled trials. But if yes, which one of the probiotics to choose?
Dr. Simmer: The one that we've been using is Infloran and the other one is one from Japan, where in the Japanese literature there has been a lot of trials, but they are the only two. Even for Infloran it took a year to get the product that was stable, so there is a lot of laboratory work before you can give it to the baby.
Dr. Szajewska: With regard to Infloran, there are two studies that used different compositions of Infloran [4, 5] . Contradictory results from the studies on Lactobacillus GG from Finland [6] and from Germany [7] show how much we need repeat studies to confirm the results. With Infloran, whatever composition it was, it was a single study.
The results were not confirmed in another study. So. I would agree with the conclusion provided we have at least another such large trial. Then, it is OK to say that this is a standard for treatment now, and now let's do other studies comparing probiotics with one which really have been proven to be effective.
Dr. Saavedra: Maybe just a couple of comments that relate to what was said earlier on the regulatory side. Unfortunately, the way the law is written is that a specific product is classified depending on what you say about it, independent of what the product does. Ultimately, it is the claim that defines the product, not the effect. So if today, and I do advise a number of fellows and postdoctoral research students who are writing their applications to NIH or any other federal funding, if you say that this trial is designed to look at the use of a particular functional product, in this case let's say it is a probiotic, a particular species or strain, for the purposes of preventing diarrhea, you will need an IND number, you will need a drug number, your fellowship will end and you didn't start the study. However, if you make the same application with the assumption that what you intend to is to look at the frequency of loose stools in children over a period of time, you will not need an IND number because you are not preventing a disease. So from that point of view, some people get lucky, get their project through, some still have a big problem, and the other next level that they have to go through is their own IRBs in the university which have exactly the same issue.
Dr. Fasano: I have been tangled with two grants that were given and then stopped until I got the IND, so it is true that in the past you had the chance to twist the system. Not anymore in the sense that now they have a panel in which lawyers, scientists and policy makers are involved, funded by the NIH to rewrite the rules because we say this is not fair, you can't change the rules while you play the game and they did exactly that, and if you like it or not, that's the way it goes. And just as a corollary when you are discussing which probiotic you use, again it doesn't matter because it's not efficacy we are talking about here. First you need to show safety, and then you talk about efficacy.
Dr. Saavedra: It may be illustrating to the audience just to get an idea of what it took to get B. lactis strain BB12 approved by FDA here. It took approximately 7 years. The safety dossier is not the clinical trials. If the incidence of infection due to a bacterium is going to be one in a thousand, you would have to study about 500,000 children to even say it's going to happen. The safety dossier for an agency like the FDA is composed first of the bacterium description itself, what is the bacterium, what does it do, does it have toxins, is it heat stable, etc. In fact, the full genome of B. lactis was presented to the FDA before the FDA approved it. So, this is how long it took, but nevertheless this is what it ultimately takes to make these steps, that is the only way to do it obviously. My other comment has to do with the quality control of the product. It is absolutely true that the majority of supplements in this country are regulated very different than food. With the supplement industry there are no rules that unfortunately are enforced to the point that you can truly be sure, and that's the point of getting an adequate manufacturer that will give you quality control data through shelf life.
